Delpha Capital Management’s Pfizer PFE Stock Holding History

Delpha Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,656	Closed	-$126K	–	911
2017 Q4	$126K	Buy	+3,656	New	+$125K	0.14%	109

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Delpha Capital Management's PFE Position: Q1 2018 in Review

Delpha Capital Management sold out of Pfizer (PFE) in Q1 2018, closing a stake of 3,656 shares — an estimated $126K sold.

Delpha Capital Management first reported a position in PFE in Q4 2017 and held it in 1 quarter. The position peaked at $126K in Q4 2017. 2,230 funds tracked by Wall St. Rank hold PFE as of Q1 2018.

Delpha Capital Management reported no remaining Pfizer position as of Q1 2018 after selling out during the quarter.
Delpha Capital Management sold 3,656 Pfizer shares in Q1 2018, an estimated $126K.
Delpha Capital Management first reported a position in Pfizer in Q4 2017 and held it in 1 quarter.
Delpha Capital Management's Pfizer position peaked at $126K in Q4 2017.
2,230 funds tracked by Wall St. Rank held Pfizer as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.